{"id":49453,"date":"2022-10-10T23:02:43","date_gmt":"2022-10-10T21:02:43","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/nanobiotix-voting-rights-and-shares-capital-of-the-company\/"},"modified":"2022-10-10T23:02:43","modified_gmt":"2022-10-10T21:02:43","slug":"nanobiotix-voting-rights-and-shares-capital-of-the-company","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/nanobiotix-voting-rights-and-shares-capital-of-the-company\/","title":{"rendered":"Nanobiotix: Voting Rights and Shares Capital of the Company"},"content":{"rendered":"
\n

\nIn accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorit\u00e9 des March\u00e9s Financiers)<\/i><\/b>\n<\/p>\n

PARIS–(BUSINESS WIRE)–$NBTX<\/a> #NBTXNews<\/a>–Regulatory News:\n<\/p>\n

<\/a><\/p>\n

\nNanobiotix (Paris:NANO) (NASDAQ:NBTX):\n<\/p>\n

\nMarket: Euronext Paris \/ Nasdaq
\n
Euronext Compartment: B
\n
ISIN code: FR0011341205
\n
Nasdaq: NBTX
\n
Bloomberg: NANO:FP
\n
Reuters: NANO.PA
\n
Website: www.nanobiotix.com<\/a>\n<\/p>\n\n\n\n\n
\n

\nDate<\/b>\n<\/p>\n<\/td>\n

\n

\nNumber of Shares
\n
Outstanding<\/b>\n<\/p>\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nTotal number of voting rights<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal voting rights,
\n
theoretical (1)<\/sup><\/b>\n<\/p>\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\nTotal voting rights,
\n
<\/b>exercisable (2)<\/sup><\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nSeptember 30, 2022\n<\/p>\n<\/td>\n

\n

\n34,875,872\n<\/p>\n<\/td>\n

\n

\n36,277,898\n<\/p>\n<\/td>\n

\n

\n36,261,825\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\n(1)<\/sup> The total number of theoretical (or \u201cgross\u201d) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.<\/i>\n<\/p>\n

\n(2)<\/sup> The total number of exercisable at a Shareholders\u2019 Meeting (or \u201cnet\u201d) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.<\/i>\n<\/p>\n

\n***<\/i>\n<\/p>\n

\nAbout NANOBIOTIX<\/b>\n<\/p>\n

\nNanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers.\n<\/p>\n

\nFor more information about Nanobiotix, visit us at www.nanobiotix.com<\/a> or follow us on LinkedIn<\/a> and Twitter<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nNanobiotix<\/i>\n<\/p>\n

\nNanobiotix Communications<\/b>
Brandon Owens<\/i>
VP, Communications<\/i>
+1 (617) 852-4835
\n
contact@nanobiotix.com<\/a>\n<\/p>\n

\nNanobiotix Investor Relations<\/b>
Kate McNeil<\/i>
SVP, Investor Relations<\/i>
+1 (609) 678-7388
\n
investors@nanobiotix.com<\/a>\n<\/p>\n

\nMedia Relations<\/i>\n<\/p>\n

\nFrance \u2013 Ulysse Communication<\/b>
Pierre-Louis Germain
\n
+ 33 (0) 6 64 79 97 51
\n
plgermain@ulysse-communication.com<\/a>\n<\/p>\n

\nLifeSci Advisors<\/b>
Ligia Vela-Reid<\/i>
+44 (0) 7413825310
\n
lvela-reid@lifesciadvisors.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorit\u00e9 des March\u00e9s Financiers) PARIS–(BUSINESS WIRE)–$NBTX #NBTXNews–Regulatory News: Nanobiotix (Paris:NANO) (NASDAQ:NBTX): Market: Euronext Paris \/ Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website: www.nanobiotix.com Date Number … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49453","6":"format-standard","7":"category-industry"},"yoast_head":"\nNanobiotix: Voting Rights and Shares Capital of the Company - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/nanobiotix-voting-rights-and-shares-capital-of-the-company\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanobiotix: Voting Rights and Shares Capital of the Company - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorit\u00e9 des March\u00e9s Financiers) PARIS–(BUSINESS WIRE)–$NBTX #NBTXNews–Regulatory News: Nanobiotix (Paris:NANO) (NASDAQ:NBTX): Market: Euronext Paris \/ Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website: www.nanobiotix.com Date Number ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/nanobiotix-voting-rights-and-shares-capital-of-the-company\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-10T21:02:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221010005340\/en\/1596550\/21\/NANOBIOTIX_RVB_NOIR_%284%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-voting-rights-and-shares-capital-of-the-company\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-voting-rights-and-shares-capital-of-the-company\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Nanobiotix: Voting Rights and Shares Capital of the Company\",\"datePublished\":\"2022-10-10T21:02:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-voting-rights-and-shares-capital-of-the-company\\\/\"},\"wordCount\":336,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-voting-rights-and-shares-capital-of-the-company\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221010005340\\\/en\\\/1596550\\\/21\\\/NANOBIOTIX_RVB_NOIR_%284%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-voting-rights-and-shares-capital-of-the-company\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-voting-rights-and-shares-capital-of-the-company\\\/\",\"name\":\"Nanobiotix: Voting Rights and Shares Capital of the Company - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-voting-rights-and-shares-capital-of-the-company\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-voting-rights-and-shares-capital-of-the-company\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221010005340\\\/en\\\/1596550\\\/21\\\/NANOBIOTIX_RVB_NOIR_%284%29.jpg\",\"datePublished\":\"2022-10-10T21:02:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-voting-rights-and-shares-capital-of-the-company\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-voting-rights-and-shares-capital-of-the-company\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-voting-rights-and-shares-capital-of-the-company\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221010005340\\\/en\\\/1596550\\\/21\\\/NANOBIOTIX_RVB_NOIR_%284%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221010005340\\\/en\\\/1596550\\\/21\\\/NANOBIOTIX_RVB_NOIR_%284%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nanobiotix-voting-rights-and-shares-capital-of-the-company\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanobiotix: Voting Rights and Shares Capital of the Company\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanobiotix: Voting Rights and Shares Capital of the Company - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/nanobiotix-voting-rights-and-shares-capital-of-the-company\/","og_locale":"en_US","og_type":"article","og_title":"Nanobiotix: Voting Rights and Shares Capital of the Company - Pharma Trend","og_description":"In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorit\u00e9 des March\u00e9s Financiers) PARIS–(BUSINESS WIRE)–$NBTX #NBTXNews–Regulatory News: Nanobiotix (Paris:NANO) (NASDAQ:NBTX): Market: Euronext Paris \/ Nasdaq Euronext Compartment: B ISIN code: FR0011341205 Nasdaq: NBTX Bloomberg: NANO:FP Reuters: NANO.PA Website: www.nanobiotix.com Date Number ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/nanobiotix-voting-rights-and-shares-capital-of-the-company\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-10T21:02:43+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221010005340\/en\/1596550\/21\/NANOBIOTIX_RVB_NOIR_%284%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/nanobiotix-voting-rights-and-shares-capital-of-the-company\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/nanobiotix-voting-rights-and-shares-capital-of-the-company\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Nanobiotix: Voting Rights and Shares Capital of the Company","datePublished":"2022-10-10T21:02:43+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nanobiotix-voting-rights-and-shares-capital-of-the-company\/"},"wordCount":336,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nanobiotix-voting-rights-and-shares-capital-of-the-company\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221010005340\/en\/1596550\/21\/NANOBIOTIX_RVB_NOIR_%284%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/nanobiotix-voting-rights-and-shares-capital-of-the-company\/","url":"https:\/\/pharma-trend.com\/en\/nanobiotix-voting-rights-and-shares-capital-of-the-company\/","name":"Nanobiotix: Voting Rights and Shares Capital of the Company - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nanobiotix-voting-rights-and-shares-capital-of-the-company\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nanobiotix-voting-rights-and-shares-capital-of-the-company\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221010005340\/en\/1596550\/21\/NANOBIOTIX_RVB_NOIR_%284%29.jpg","datePublished":"2022-10-10T21:02:43+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/nanobiotix-voting-rights-and-shares-capital-of-the-company\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/nanobiotix-voting-rights-and-shares-capital-of-the-company\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/nanobiotix-voting-rights-and-shares-capital-of-the-company\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221010005340\/en\/1596550\/21\/NANOBIOTIX_RVB_NOIR_%284%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221010005340\/en\/1596550\/21\/NANOBIOTIX_RVB_NOIR_%284%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/nanobiotix-voting-rights-and-shares-capital-of-the-company\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Nanobiotix: Voting Rights and Shares Capital of the Company"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49453","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49453"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49453\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49453"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49453"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49453"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}